Mark Hahn also works closely with David Ebsworth, Chairman of Opterion Health, at Verona Pharma. Their ongoing collaboration ...

DoseSpot CEO Josh Weiner points out that a $10.2M savings across 100K+ prescriptions in 3 months extrapolated out across the 32.8M Americans currently taking GLP-1 medication monthly indicates a ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

About Dr. Anosh Ahmed Dr. Anosh Ahmed is a Chicago-based physician, entrepreneur, and Republican figure recognized for ...

In 2022, Idorsia and Simcere entered into an exclusive licensing agreement for Idorsia’s QUVIVIQ in China. Under the agreement, Simcere has an exclusive right to develop and commercialize QUVIVIQ in ...

“I am excited to join Galapagos at this pivotal moment,” said Aaron Cox, incoming CFO of Galapagos. “I look forward to working with Henry and the talented team to help shape the company’s next chapter ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in ...

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,308,783 A shares and 108,825,495 B shares. The number of votes of the company's shares is ...

Masitinib is a highly innovative drug for Alzheimer’s disease because unlike the majority of drug development research in this indication, masitinib targets the brain’s innate immune system, including ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma. Recommendation based on GMMG-HD7 phase 3 study demonstrating that S ...

Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of ...